You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Poly ADP-Ribose Polymerase (PARP) inhibitor.

Showing 1 - 25 of 8,550
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

Active, not recruiting
  • Ovarian Neoplasms
  • +2 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • Brussels, Belgium
  • +4 more
Dec 19, 2022

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

Recruiting
  • Solid Tumor
  • +6 more
  • HoĊ™ovice, Czechia
  • +5 more
Jun 8, 2022

Tumors, Breast Tumors Trial in Japan (talazoparib)

Active, not recruiting
Has Results
  • Neoplasms
  • Breast Neoplasms
  • Nagoya, Aichi, Japan
  • +7 more
Dec 20, 2021

Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)

Recruiting
  • Recurrent Glioma
  • +4 more
  • Hong Kong, Hong Kong
    Department of Clinical Oncology
Aug 19, 2021

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Homologous Recombination Deficiency in Chinese Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • PARP inhibitor
  • Nanjing, Jiangsu, China
    Xiaoxiang Chen, MD,PhD
Sep 4, 2021

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States

Active, not recruiting
  • Metastatic Malignant Solid Neoplasm
  • +4 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Phoenix, Arizona
  • +14 more
Sep 1, 2022

Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)

Active, not recruiting
  • Prostate Cancer
  • [18F]FluorThanatrace
  • Poly(ADP Ribose) Polymerase 1
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
May 12, 2022

Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022

Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle

Recruiting
  • Sarcoma,Soft Tissue
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Endometrial Cancer Trial in Canada (Niraparib, TSR-042)

Active, not recruiting
  • Endometrial Cancer
  • Calgary, Alberta, Canada
  • +6 more
Nov 18, 2021

Breast Tumors, Triple-Negative, Breast Tumor Malignant Female, Radiotherapy Side Effect Trial in Paris (Olaparib, Radiation

Active, not recruiting
  • Breast Neoplasms, Triple-Negative
  • +2 more
  • Paris, France
    Institut Curie
Oct 23, 2020

Squamous Cell Carcinoma of the Head and Neck Trial (Olaparib)

Withdrawn
  • Squamous Cell Carcinoma of the Head and Neck
  • (no location specified)
Jan 9, 2020

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

Completed
  • Ovarian Cancer
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 3, 2022

Metastatic Prostate Cancer Trial in Boston (Enzalutamide, Niraparib)

Terminated
Has Results
  • Metastatic Prostate Cancer
  • Boston, Massachusetts
    Tufts Medical Center
Oct 18, 2019

Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

Completed
  • Metastatic Cancer
  • Unspecified Adult Solid Tumor
  • PARP inhibitor BMN-673
  • +4 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Sep 22, 2022

Breast Cancer Trial in Tucson (Rucaparib)

Active, not recruiting
  • Breast Cancer
  • Tucson, Arizona
    University of Arizona Cancer Center
Feb 24, 2022

Ovarian Cancer Trial in Worldwide (Olaparib, Ceralasertib, Placebo to match olaparib)

Withdrawn
  • Ovarian Cancer
  • Anchorage, Alaska
  • +25 more
Mar 9, 2021

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or

Completed
  • Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
  • Avelumab Phase 1b
  • +3 more
  • Fayetteville, Arkansas
  • +57 more
Jan 18, 2023

Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy, Diagnostic Imaging, Novobiocin Sodium)

Not yet recruiting
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
  • Biopsy
  • +2 more
  • (no location specified)
Jan 14, 2023